UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
May 20, 2008
Date of Report (Date of earliest event reported)
Medistem Laboratories, Inc.
(Exact name of registrant as specified in its charter)
Nevada
333-100137
86-1047317
(State or other jurisdiction
of incorporation)
(Commission File Number)
(IRS Employer Identification
No.
2223 West Pecos Road, Suite 6, Chandler, Arizona
85224
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code: (954) 727-3662
Not applicable.
(Former name or former address, if changed since last report.)
_____________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ]
Written communications pursuant to Rule 425 under Securities Act (17 CFR 230.425)
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On May 16, 2008, Chris McGuinn resigned from his position as Chief Operating Officer of Medistem Laboratories, Inc. (the “Company”) to pursue other business opportunities. On May 20, 2008, the Company issued a press release announcing Mr. McGuinn’s resignation. The full text of the Company’s press release is attached hereto as Exhibit 99.1. The Company has no current plans for replacing Mr. McGuinn and for the time being will divide his responsibilities among its existing employees.
Item 9.01. Financial Statements and Exhibits.
Exhibit No.
Description
99.1
Press Release regarding Chris McGuinn’s resignation, dated May 20, 2008.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
MEDISTEM LABORATORIES, INC.
Date: May 20, 2008
By: /s/ Steve Rivers
Name: Steve Rivers
Title: Chief Financial Officer
3